The UK government has doubled the rate that pharmaceutical companies repay on the sales of newer products to the NHS under the statutory scheme for branded medicines to a record 31%. Following a consultation, the government has decided to raise the statutory scheme payment rate for newer branded medicines from 15.5% to 31.3% of subject […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!